Good one.
I like the focus on mtor, I like less the idea that current mtor drugs ended up being dissapointing and the cancer became resistant quite quickly.
In saying that, the market for Sirolimus and Everolimus is still around 2.5b per annum according to the PAA slides....so while perhaps dissapointing in their trials, ultimately still financially profitable. Let's hope our mtor out performs massively in cancer trials (and covid)...
Ann: Virtual Investor Briefing Presentation, page-149
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $73.24M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.5¢ | 17.5¢ | $68.67K | 382.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 203260 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 57357 | 5 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.0¢ |
Change
0.005 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 17.8¢ | 18.0¢ | 17.5¢ | 253129 | ||
| Last updated 15.56pm 27/05/2024 ? | |||||
| PAA (ASX) Chart |